• Strong 1H26 results with revenue up 14.9%, EBIT up 18.7% and NPAT up 19.2%
• Domestic and international operations delivered solid growth, with CW branded store sales up 17.2% and international store sales up 24.5%
• Transformation and integration programs tracking to plan with $13m synergies achieved

Sigma Healthcare Ltd reported strong 1H26 results, with revenue, EBIT and NPAT growing by 14.9%, 18.7% and 19.2% respectively compared to the prior corresponding period. The company's domestic operations, including the Chemist Warehouse (CW) branded store network, delivered robust growth, with CW branded store sales up 17.2% and like-for-like sales up 15.0%. The international operations also accelerated, with network sales up 24.5% and like-for-like sales up 11.1%. The transformation and integration programs are tracking to plan, with $13m in synergies achieved in 1H26. Sigma continues to focus on executing its key strategic growth pillars, including maintaining market leadership in the domestic market, driving profitable growth in international operations, expanding its owned and exclusive label product portfolio, and leveraging the combined scale of the business to drive operating leverage and efficiency. The company remains conservatively leveraged, with a net debt to EBITDA ratio of 0.6x, providing flexibility to self-fund growth initiatives.

Sigma expects to onboard 9 new Chemist Warehouse pharmacies and 15 Amcal franchisees in Australia, as well as 11 new Chemist Warehouse stores in its international markets, in 2H26. The company remains on track to achieve its $100m per annum synergy target by FY29.

Sigma's domestic trading in the first 7 weeks of 2H26 has remained strong, with Chemist Warehouse branded store sales up 16.6% and like-for-like sales up 14.4%. The company continues to execute targeted investments that support scale and efficiency across its operations.